<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S3224 IS: Dangerous Synthetic Drug Control Act of 2016</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2016-07-14</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>2d Session</session>
		<legis-num>S. 3224</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20160714">July 14, 2016</action-date>
			<action-desc><sponsor name-id="S153">Mr. Grassley</sponsor> (for himself, <cosponsor name-id="S270">Mr. Schumer</cosponsor>, <cosponsor name-id="S287">Mr. Cornyn</cosponsor>, <cosponsor name-id="S221">Mrs. Feinstein</cosponsor>, and <cosponsor name-id="S311">Ms. Klobuchar</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for
			 other purposes. </official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Dangerous Synthetic Drug Control Act of 2016</short-title></quote>.</text>
		</section><section id="idb732285595f64be8946eda852da12076"><enum>2.</enum><header>Treatment of certain designer drugs as schedule I controlled substances</header>
 <subsection id="id7657c3f086e941c1884fa706dae905c1"><enum>(a)</enum><header>Cannabimimetic agents</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (d)(2)(B)—</text>
 <paragraph id="id08C43B8C40914D21BBC0D66E83BDEA6A"><enum>(1)</enum><text>in clause (xiv) by striking <quote>and</quote> at the end;</text> </paragraph><paragraph id="id77fc0aa7a2e14ff5b0c072b7de493021"><enum>(2)</enum><text>in clause (xv) by striking the period and inserting a semicolon; and</text>
 </paragraph><paragraph id="idd2ba46968e1c4ee080823737c45b5b03"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="id29f56167d7a3406281b1a033de612d2e" style="OLC"> <clause id="id9e04df7f357546dfa55c024254ea088c"><enum>(xvi)</enum><text>2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251);</text>
 </clause><clause id="idac830916e1ec4532ad97dd7bb8cb22ff"><enum>(xvii)</enum><text>(1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073);</text> </clause><clause id="id3fa4fe6586ea4ae89941cacec48ed7e7"><enum>(xviii)</enum><text>2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302);</text>
 </clause><clause id="id36618fe496474e38819a18d57ea59516"><enum>(xix)</enum><text>N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA);</text> </clause><clause id="idf9a3198559d543788d99eedae70a0eac"><enum>(xx)</enum><text>quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22);</text>
 </clause><clause id="id744fd5c336fd4e36bd5d57cacede489b"><enum>(xxi)</enum><text>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA);</text> </clause><clause id="id556296ef43594c87b860a3ec8b01234a"><enum>(xxii)</enum><text>N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24);</text>
 </clause><clause id="idf5fe5f95ba874e0a9be639c9e672df50"><enum>(xxiii)</enum><text>(1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201);</text> </clause><clause id="ida297ff48d7454a24aa44e24466f4df13"><enum>(xxiv)</enum><text>N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA);</text>
 </clause><clause id="idf82901135f87448b804ef9cf04d504ab"><enum>(xxv)</enum><text>methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and</text> </clause><clause id="idac291c021d3b4e5f8a8ac94bdd96ddf0"><enum>(xxvi)</enum><text>methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MACHMINACA).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="id72a94a82468e4255af5c314281154aaf"><enum>(b)</enum><header>Synthetic opioids</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (a) by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id3d903fc9e1094c21916bfcdf864b3ce1" style="OLC">
 <paragraph id="id246835a902d04c7eb8387fd9a6d99873"><enum>(43)</enum><text>Butyryl fentanyl.</text> </paragraph><paragraph id="id452eb353869d42fab78d7efb6058e38f"><enum>(44)</enum><text>beta-Hydroxythiofentanyl.</text>
 </paragraph><paragraph id="ida8bee206f7cf4e139ab4234f8d8342ae"><enum>(45)</enum><text>Acetyl fentanyl.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="id5b331056138f4dca873c0c5f216495c4"><enum>(c)</enum><header>Other drugs</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (c) by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="idf216580f878749cd89ab062c599e7200" style="OLC">
 <paragraph id="id4626dee8cb1744609380ee535c509192"><enum>(29)</enum><text>1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone).</text> </paragraph><paragraph id="id44f1c958418a4bf6b653581f4e3ab47b"><enum>(30)</enum><text>1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB).</text>
 </paragraph><paragraph id="id4041ad1365754cd1b99a4d663f88748a"><enum>(31)</enum><text>1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB).</text> </paragraph><paragraph id="idbcae4ad7a5f9421cb711b76f3a4317b0"><enum>(32)</enum><text>6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI).</text>
 </paragraph><paragraph id="id552770a97f0d40de84c21c0ec0fdb939"><enum>(33)</enum><text>5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI).</text> </paragraph><paragraph id="idc66b9bdbfb604bae9caa1bd34b2c32ec"><enum>(34)</enum><text>1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly).</text>
 </paragraph><paragraph id="idc1c90f5dd531496981626e8ea7e40f87"><enum>(35)</enum><text>1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC).</text> </paragraph><paragraph id="id670e941151f54e41af382ba0374ca7bd"><enum>(36)</enum><text>1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section></legis-body>
</bill>


